Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT00428220
Official study title

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Study summary

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedsunitinib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 27, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?113 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Pfizer
Interventions being studied
Drug: sunitinib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Must have ended treatment from one of the following sunitinib studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

Reasons someone may not be able to joinExclusion criteria

See inclusion criteria

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Emory University, Winship Cancer InstituteAtlanta, Georgia
  • Investigational Drug ServiceAtlanta, Georgia
  • The Emory ClinicAtlanta, Georgia
  • Loyola University Medical CenterMaywood, Illinois
  • University of Iowa Hospitals and ClinicsIowa City, Iowa
  • Siteman Cancer CenterCity of Saint Peters, Missouri
  • Siteman Cancer Center-West CountyCreve Coeur, Missouri
  • Barnes Jewish HospitalSt Louis, Missouri
  • Washington University School of Medicine, Siteman Cancer CenterSt Louis, Missouri
  • Comprehensive Cancer Center of NevadaLas Vegas, Nevada
  • Comprehensive Cancer Centers of NevadaLas Vegas, Nevada
  • Northwest Cancer Specialists, P.C.Portland, Oregon

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 27, 2019. Always confirm current availability with the study team.

View original record ↗